Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression

  title={Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression},
  author={Leor Roseman and David J. Nutt and Robin Lester Carhart-Harris},
  journal={Frontiers in Pharmacology},
Introduction: It is a basic principle of the “psychedelic” treatment model that the quality of the acute experience mediates long-term improvements in mental health. In the present paper we sought to test this using data from a clinical trial assessing psilocybin for treatment-resistant depression (TRD). In line with previous reports, we hypothesized that the occurrence and magnitude of Oceanic Boundlessness (OBN) (sharing features with mystical-type experience) and Dread of Ego Dissolution… 

Figures and Tables from this paper

Psilocybin-Induced Mystical-Type Experiences are Related to Persisting Positive Effects: A Quantitative and Qualitative Report

Psychedelic drugs such as psilocybin have shown substantial promise for the treatment of several psychiatric conditions including mood and addictive disorders. They also have the remarkable property

Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression

Background: Across psychotherapeutic frameworks, the strength of the therapeutic alliance has been found to correlate with treatment outcomes; however, its role has never been formally assessed in a

Antidepressant effects of a psychedelic experience in a large prospective naturalistic sample

Investigation of changes in anxiety and depression scores before versus after psychedelic experiences in naturalistic contexts lends support to therapeutic potential of psychedelics and highlight the influence of pharmacological and non-pharmacological factors in determining response.

Psilocybin Efficacy and Mechanisms of Action in Major Depressive Disorder: a Review

Psilocybin has a large, rapid, and persistent clinical effect in the treatment of resistant or end-of-life depression, with mild side effects limited to a few hours after dosing.

Dose–response relationships of psilocybin-induced subjective experiences in humans

Psilocybin intensified almost all characteristics of altered states of consciousness assessed with the given questionnaires, and the results may only apply to controlled laboratory experiments and not to recreational use.

The therapeutic potential of psilocybin: a systematic review

The findings of these studies collectively show that psilocybin has a positive benefit–risk balance in the treatment of various mental disorders with an immediate and prolonged effect following 1–3 doses of p silocybin and a few (serious) adverse events.

Psychedelics, Mystical Experience, and Therapeutic Efficacy: A Systematic Review

The mystical experience is a potential psychological mechanism to influence outcome in psychedelic therapy. It includes features such as oceanic boundlessness, ego dissolution, and universal

Rediscovering Psilocybin as an Antidepressive Treatment Strategy

An overview of the current state of research on the potential mechanisms of psilocybin, its antidepressant potential, and the associated risks and adverse effects is provided to provide an update on a controversial topic discussed in psychopharmacology.

Psychedelic assisted therapy for major depressive disorder: Recent work and clinical directions

Psychedelic substances such as psilocybin and ketamine may represent the future of antidepressant treatment, due to their rapid and prolonged effects on mood and cognition. The current body of

Trial of Psilocybin versus Escitalopram for Depression.

This phase 2, double-blind, randomized, controlled trial involving patients with long-standing, moderate-to-severe major depressive disorder did not show a significant difference in antidepressant effects between psilocybin and escitalopram in a selected group of patients.



Psilocybin with psychological support for treatment-resistant depression: six-month follow-up

Although limited conclusions can be drawn about treatment efficacy from open-label trials, tolerability was good, effect sizes large and symptom improvements appeared rapidly after just two psilocybin treatment sessions and remained significant 6 months post-treatment in a treatment-resistant cohort.

Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study

A single-group proof-of-concept study to quantify acute effects of psilocybin in alcohol-dependent participants and to provide preliminary outcome and safety data, providing a strong rationale for controlled trials with larger samples to investigate efficacy and mechanisms.

Peak experiences and the afterglow phenomenon: When and how do therapeutic effects of hallucinogens depend on psychedelic experiences?

This review aims to re-evaluate earlier and recent concepts of how psychedelic substances may exert beneficial effects, and summarizes evidence for the relationship between subjective experiences and therapeutic success.

Psychedelics in the treatment of unipolar mood disorders: a systematic review

The evidence overall strongly suggests that psychedelics should be re-examined in modern clinical trials for their use in unipolar mood disorders and other non-psychotic mental health conditions.

Psychedelics and the essential importance of context

This article highlights the pharmacological mechanisms of classic psychedelics that it is believed render their effects exceptionally sensitive to context, and develops an evidence base for long-held assumptions about the critical importance of context in relation to psychedelic use that can help minimise harms and maximise potential benefits.

Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial

Psilocybin was associated with enduring anxiolytic and anti-depressant effects in patients with cancer-related psychological distress, sustained benefits in existential distress and quality of life, as well as improved attitudes towards death.

Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial

High-dose psilocybin produced large decreases in clinician- and self-rated measures of depressed mood and anxiety, along with increases in quality of life, life meaning, and optimism, and decreases in death anxiety.

The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms

Seven Challenging Experience Questionnaire factors provide a phenomenological profile of challenging aspects of experiences with psilocybin that provides a basis for future investigation of predictors and outcomes of challenging experiences with classic hallucinogens.

Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance

When administered under supportive conditions, psilocybin occasioned experiences similar to spontaneously occurring mystical experiences, and the ability to occasion such experiences prospectively will allow rigorous scientific investigations of their causes and consequences.